Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells $25,606.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total transaction of $25,606.00. Following the completion of the transaction, the director owned 420 shares in the company, valued at $215,090.40. The trade was a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jan Malcolm also recently made the following trade(s):

• On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $482.98, for a total transaction of $24,149.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $513.99 on Friday. The stock’s 50-day moving average is $469.90 and its 200-day moving average is $385.83. The company has a market cap of $22.13 billion, a P/E ratio of 19.48, a P/E/G ratio of 5.11 and a beta of 0.86. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.39 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Oppenheimer boosted their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $505.00.

Institutional Trading of United Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Clearstead Advisors LLC lifted its holdings in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares during the period. Bessemer Group Inc. lifted its holdings in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares during the last quarter. Archer Investment Corp lifted its holdings in United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 31 shares during the last quarter. F m Investments LLC boosted its position in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 33 shares in the last quarter. Finally, HB Wealth Management LLC grew its stake in United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after buying an additional 35 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.